53.20
0.00 (0.00%)
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Enanta Pharmaceuticals Inc | ENTA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| -0.12 | -0.23% | 53.20 | 52.76 | 54.53 | 53.25 | 53.32 | 16:43:46 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 43.44 | 54.00 | 10.56 | 19.56% | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,316 | 210,519 | $ 53.40 | $ 11,242,477 | 219,411 | 51.00 - 106.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:12:32 | average | 14,600 | $ 53.20 | USD |
Enanta Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 1.06B | 19.92M | $ 71.96M | 2.22 | 32.90 | 18.80M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Enanta Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ENTA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 52.58 | 54.53 | 51.29 | 52.93 | 153,619 | 0.62 | 1.18% |
| 1 Month | 56.12 | 58.38 | 51.00 | 53.70 | 180,035 | -2.92 | -5.2% |
| 3 Months | 63.52 | 67.88 | 51.00 | 59.00 | 189,036 | -10.32 | -16.25% |
| 6 Months | 72.79 | 73.98 | 51.00 | 61.61 | 186,979 | -19.59 | -26.91% |
| 1 Year | 100.30 | 106.80 | 51.00 | 75.21 | 189,183 | -47.10 | -46.96% |
| 3 Years | 29.25 | 127.77 | 27.241 | 72.08 | 207,709 | 23.95 | 81.88% |
| 5 Years | 35.90 | 127.77 | 16.75 | 53.65 | 228,412 | 17.30 | 48.19% |
Enanta Pharmaceuticals Description
| Enanta Pharmaceuticals Inc is an American biotechnology company focused on research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline. |
